Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders

Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study

Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence

Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441

Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)

Addex Shareholders Approve All Board Proposals at Annual General Meeting